The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise—including aseptic fill & finish—and regulatory-grade quality systems. Together, the companies provide a seamless model that minimizes tech-transfer delays, reduces the risk of costly cell line rebuilds, and accelerates the delivery of IND-enabling and clinical material. One cell line. One tech transfer. One faster path to the clinic.

A Partnership Designed to Reduce Risk and Gain Time 

The joint offering addresses some of the most common challenges faced by biotech companies: long development cycles, technical bottlenecks, and costly delays that impact valuation and fundraising timelines. By streamlining CLD and GMP manufacturing, customers gain a clear, uninterrupted path from early development to high-quality material suitable for clinical studies. For early-stage biotech companies operating against tight funding timelines, even a three-month delay can materially impact valuation and financing outcomes. 

“Partnering with Demeetra strengthens our ability to support biotech companies all the way, with a rapid, reliable, and continuous path to GMP material,” said Janet Hoogstraate, CEO of NorthX Biologics. “Biotech companies no longer need to choose between best-in-class cell line development and proven GMP execution. Our collaboration with Demeetra provides an optimal solution for development of biologics.” 

“We are excited to collaborate with NorthX Biologics,” said Jack Crawford, CEO of Demeetra. “Demeetra’s platforms are designed to produce cell lines that go straight into manufacturing without rebuilds or licensing conversations downstream. Partnering with NorthX Biologics closes the loop. Together we’ve built a high-performance, end-to-end path that protects both the program timeline and the full economic value of the client’s asset.” 

Key Customer Benefits 

• Royalty-free cell line development – molecule retains full economic value through fundraising, partnering or acquisition 

• A single, coordinated team – direct transition from CLD to GMP manufacturing with no re-qualification 

• Reduced technical and regulatory risk 

• Shorter timelines to IND/Phase I 

The Demeetra and NorthX Biologics collaboration reflects a shared commitment to reducing fragmentation in early biologics development. By integrating genome engineering, cell line development, upstream processing, and GMP execution within a coordinated framework, the companies aim to simplify decision-making for biotech leaders and reduce the cumulative risk associated with multi-vendor handoffs. 

About NorthX Biologics 
NorthX Biologics is a leading contract development and manufacturing organization (CDMO) and Sweden’s national innovation hub for advanced biologics, enabling next-generation therapies beyond traditional manufacturing. With over 30 years of GMP experience, NorthX Biologics offers end-to-end services including process development, recombinant proteins, vaccines, viral vectors, cell therapies, and aseptic fill & finish. With its headquarters in Matfors, Sweden, and a facility in Stockholm, NorthX Biologics serves customers worldwide. 

For more information, please contact: 
Janet Hoogstraate 
Chief Executive Officer 
Email: janet.hoogstraate@nxbio.com 
Website: www.nxbio.com 

About Demeetra 
Demeetra is a genome engineering company providing integrated platforms for gene editing, transposon-based integration, and cell line development. Demeetra’s technologies deliver high performance with clear intellectual property lineage, enabling confident adoption across research, development, and biomanufacturing workflows.